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Abstract
Introduction Research on associations between medica-
tion use during pregnancy and congenital anomalies is
significative for assessing the safe use of a medicine in
pregnancy. Congenital anomaly (CA) registries do not have
optimal information on medicine exposure, in contrast to
prescription databases. Linkage of prescription databases to
the CA registries is a potentially effective method of
obtaining accurate information on medicine use in preg-
nancies and the risk of congenital anomalies.
Methods We linked data from primary care and pre-
scription databases to five European Surveillance of Con-
genital Anomalies (EUROCAT) CA registries. The linkage
was evaluated by looking at linkage rate, characteristics of
linked and non-linked cases, first trimester exposure rates
for six groups of medicines according to the prescription
data and information on medication use registered in the
CA databases, and agreement of exposure.
Results Of the 52,619 cases registered in the CA data-
bases, 26,552 could be linked. The linkage rate varied
between registries over time and by type of birth. The first
trimester exposure rates and the agreements between the
databases varied for the different medicine groups. Infor-
mation on anti-epileptic drugs and insulins and analogue
medicine use recorded by CA registries was of good
quality. For selective serotonin reuptake inhibitors, anti-
asthmatics, antibacterials for systemic use, and gonado-
tropins and other ovulation stimulants, the recorded infor-
mation was less complete.
A presentation was given at the 54th Annual Meeting of the
Teratology Society in Washington, USA, 28 June–2 July 2014.
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Key Points
Linkage of primary care or prescription databases to
congenital anomaly (CA) registries improved the
quality of information on maternal use of medicines
in pregnancy.
The quality of information improved particularly for
medicine groups that are less fully registered in CA
registries, such as selective serotonin reuptake
inhibitors, anti-asthmatics, antibacterials for
systemic use, and gonadotropins and other ovulation
stimulants.
Drug Saf (2015) 38:1083–1093
DOI 10.1007/s40264-015-0321-9
Conclusion Linkage of primary care or prescription
databases to CA registries improved the quality of infor-
mation on maternal use of medicines in pregnancy, espe-
cially for medicine groups that are less fully registered in
CA registries.
1 Introduction
Medicines are commonly used during pregnancy: approx-
imately 80 % of all women use at least one medicine
during pregnancy [2]. Although the use of some medicines
is unavoidable for serious or chronic conditions, fetal
exposure may increase the risk of a congenital anomaly
(CA). One example is the anti-epileptic medication val-
proic acid, which increases the risk of having a child with
spina bifida if taken in the first trimester of pregnancy [3].
However, little is known regarding the teratogenic effects
of many medicines. Research on possible associations
between medicine use during pregnancy and CAs is of
great importance for assessing the safe use of a medicine in
pregnancy. Since CAs are rare outcomes, and medicine
needs to be analysed in specific groups or as specific drugs,
we need to study large datasets with accurate and detailed
information on the type and timing of medicine exposure in
pregnancy and the type of a possibly related CA.
The European Surveillance of Congenital Anomalies
(EUROCAT) network consists of 43 population-based
registries set up for the epidemiological surveillance of
CAs; the network covers 29 % of all births in Europe [4–
6]. These registries hold information on fetuses and chil-
dren with CAs, and associated factors such as maternal
medicine use in pregnancy. Most of the registries retrieve
information on first-trimester maternal medicine use from
medical files, which may be limited and incomplete [7].
Prescription databases, which are increasingly being
used to explore associations between medicine use in
pregnancy and CAs [8–11], contain more complete
information on medicine use than CA registries, and pre-
scribing information is prospectively collected. Given the
quality of information on medicine exposure that is
recorded in both CA registries and prescription databases,
linking prescription databases to the EUROCAT CA reg-
istries is a potentially effective method of obtaining accu-
rate information on medicine use in pregnancies that were
complicated by fetal CA.
In this study we linked administrative prescription
databases with five CA registries. We present the results for
six selected groups of medicines: anti-epileptic medicines
[Anatomical Therapeutic Chemical (ATC) code [12]
N03A], insulins and analogues (A10A), selective serotonin
reuptake inhibitors (SSRIs) (N06AB), anti-asthmatics
(R03), antibacterials for systemic use (J01), and gonado-
tropins and other ovulation stimulants (G03G).
This research was embedded in the EUROmediCAT
project [13], which stimulates the collaboration of health-
care databases and EUROCAT registries. EUROmediCAT
is a Seventh Framework Programme study funded by the
European Union.
2 Methods
In this study, prescription/primary care databases were
linked to five EUROCAT CA registries:
• Wales: the general practitioner (GP) data in the Secure
Anonymised Information Linkage (SAIL) Databank
[14, 15] was linked to the Welsh CA registry
[Congenital Anomaly Register and Information Service
(CARIS)];
• Norway: Reseptregisteret [Norwegian Prescription
Database (NorPD)] was linked to the Medical Birth
Registry from Norway (MBRN) [16, 17];
• Odense, Denmark: Laegemiddelstatistikregisteret
(Danish National Prescription Registry) [18] was linked
to the CA registry of Odense, Denmark;
• Emilia Romagna, Italy: Emilia Romagna Prescription
Database (ERPD) [19] was linked to Emilia Romagna
CA registry (IMER), Italy;
• Tuscany, Italy: Assistenza Farmaceutica Territoriale
(AFT; Pharmaceutical Territorial Assistance) and Far-
maci a Erogazione Diretta (FED; Medicine Directly
Dispensed by the Health System) [20] were linked to
the CA registry of Tuscany, Italy (RTDC; Tuscan
Registry of Congenital Defects).
The CA registries collect data on fetuses and infants
with CAs, including live births (LB), fetal deaths (FDs)
C20 weeks of gestational age (including stillbirths) and
terminations of pregnancy for fetal anomaly (TOPFA).
Information on date of birth, gestational age at birth,
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10 Institute of Clinical Physiology, National Research Council
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maternal age, long-term diseases, maternal medicines and
disease exposures during pregnancy are also collected. The
first trimester of pregnancy is defined according to the
EUROCAT Guide [21] as the period from the first day of
the last menstrual period (LMP) up to 12 completed weeks
of gestation (day 0 to day 83).
The primary care or prescription databases involved in
our linkage effort are population-based administrative
databases that contain data on medicines prescribed and/or
dispensed. In the linked prescription data, the first trimester
was defined as the period from the first day of the LMP as
recorded in the CA database up to 14 completed weeks of
gestation (day 0 to day 97). If the LMP was unknown, it
was calculated as the date of birth of the child minus the
gestational age at birth as recorded in the CA database. If
the gestational age at birth was unknown, a standardised
length of 280 days (40 weeks) for live births and 224 days
(32 weeks) for still births was used. If the gestational age
was unknown for a TOPFA case, the average age for
TOPFAs for the respective registry across the whole of the
included time period was used. Characteristics of the pri-
mary care/prescription databases and the CA registries
have been described in detail elsewhere [5, 7, 22, 23].
Table 1 summarises the birth years, the number of CA
cases registered in the study period, the registry sources for
maternal medicine use, whether the medicine recorded in
the CA data was based on the first trimester only or for the
whole pregnancy and the proportion of cases with at least
one medicine recorded in the CA database.
We applied a distributed database model, in which the
linkage was performed locally for all registries and the
linked datasets were kept locally [24]. The linkage was
performed by matching identification numbers and/or
maternal characteristics in both the primary care/prescrip-
tion and the CA databases. For CA cases identified in the
primary care/prescription databases, the information held
on medicine use was added to the information in the CA
registry. Details of the linkage process have been described
elsewhere [25].
An Access-based software module, the Linkage Data
Management Program (LDMP), was developed for this
project and used to ensure validated datasets. The LDMP
was used to import and export data, validate data, and
generate tables for evaluation and analyses. The use of the
LDMP ensured the compatibility of anomaly subgroups
and medicine groups among the participating registries and
allowed tables to be generated in a uniform way. To
evaluate the linkage effort, the participating registries
provided tables generated by LDMP. Since the Danish
regulations do not allow external software to be used on
their server, Odense, Denmark was not able to import their
data via the LDMP. They generated the aggregated tables
locally and generated the tables manually, using the same
selection criteria and definitions as in the LDMP.
In the analyses, cases that met the EUROCAT case
definition were included: cases with major CA defined by
the Q-chapter of the International Classification of Dis-
eases, 10th revision (ICD-10), or in the range 740–759 of
the International Classification of Diseases, 9th revision
(ICD-9), and a very limited set of conditions not included
in the Q chapter [21]. Cases with isolated minor anomalies
were excluded from the EUROCAT case definition.
Using the LDMP, each registry evaluated the linkage on
the following aspects:
• Linkage success: defined as the proportion of cases in
the CA database that could be linked to the primary
care/prescription data.
• Comparison of the linked and non-linked cases: since
not all the cases could be linked, we considered it
relevant to compare both groups on year of birth and
type of birth. A Chi-squared (v2) test was performed for
both factors to determine the statistical significance. If
20 % of the cells in the contingency table had less than
five observations, a Fisher Exact test was performed
instead of the v2 test. The statistical tests were
performed in PASWStatistics 22 (IBM SPSS Statistics
for Windows, Version 22.0. IBM Corp., Armonk, NY).
• Comparison of data on first trimester medicine use: the
‘first trimester exposures rates’ and the ‘agreement of
exposure’ were calculated as described in Table 2 to
compare the data. These factors were calculated for six
groups of medicines: anti-epileptic medicines, insulins
and analogues, SSRIs, anti-asthmatics, antibacterials
for systemic use, and gonadotropins and other ovulation
stimulants. The agreement according to the primary
care/prescription data may be influenced by the defini-
tion of first trimester exposure (date of prescription in
the period 0–97 days); therefore, we also calculated the
agreement using a broader first-trimester definition (-
31 to ?97 days after the LMP).
3 Results
The five CA databases included 52,619 cases in total, of
which 65.7 % (n = 34,547) could be linked. The propor-
tion of cases that could be linked ranged from 31.7 % in
Wales (where 40 % of the primary care practices con-
tribute prescription data to the voluntary SAIL database) to
100 % in Odense, Denmark. Of the 34,547 registered cases
that were linked to prescription databases, 26,552 (76.9 %)
met the EUROCAT case definition as described in Sect. 2
(Table 3).
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The linked and non-linked EUROCAT cases were
compared for year of birth and type of birth for the reg-
istries with less than 100 % linkage success (Table 4).
There was a significant difference between the linked and
non-linked cases for all registries in year of birth. For
Wales, Emilia Romagna and Tuscany, the rate of linked
cases increased over time, while the number of linked cases
decreased over time in Norway. For type of birth, there
were no differences between linked and non-linked cases
for Wales and Norway. For Emilia Romagna, TOPFA
cases were only seen in the non-linked group, while for
Tuscany there were fewer live births (74.0 vs. 86.2 %) but
more TOPFA cases (25.1 vs. 12.6 %) in the linked group.
The first trimester exposure rates according to the CA
data and the primary care/prescription database are shown
in Table 5. For the anti-epileptic medicines and the insulins
and analogues, there were small, but potentially clinically
important, differences between the first trimester exposure
rates based on the CA registries and the primary care or
prescription database. The first trimester exposure rates for
anti-asthmatics also revealed small differences between
those recorded in the CA registries and in the primary care
or prescription database per registry, except for Tuscany.
For Tuscany, the first trimester exposure rate recorded in
the prescription database was more than six times higher
than the rate recorded in the CA registry. For the SSRIs, the
first trimester exposure rates recorded in the primary care
or prescription database were two to three times higher
Table 1 Summary of birth years, number of cases and the sources of information on maternal medicine use per registry
Wales Norway Odense,
Denmark
Emilia Romagna Tuscany
Birth years included in the linkage 1998–2010 2004–2010 1998–2010 2004–2010 2003–2010
Number of cases registered in study period 17,244 21,136 2006 6410 5823
Sources for maternal use of medicines used
by the congenital anomalies registry [7]
Medical files
from:
Healthcare
providers in
relation to
pregnancy
Medical files
from:
Healthcare
providers in
relation to
pregnancy
Healthcare
providers of
the child
Medical files
from:
Healthcare
providers in
relation to
pregnancy
Healthcare
providers of
the child
Medical files from:
Healthcare providers in
relation to pregnancy
Healthcare providers of
the child
Healthcare providers
not in relation to
pregnancy
(prescription data)
Questionnaire
Period of medicine use recorded in
congenital anomalies data [7]
1st trimester Whole
pregnancy
1st trimester Whole pregnancy 1st trimester
Proportion of cases with at least one
medication, including vitamins and
minerals, recorded for the years
2004–2010 [7]
15.6 % 22.4 % 17.7 % 33.8 % 13.2 %
CARIS Congenital Anomaly Register and Information Service, MBRN Medical Birth Registry from Norway, RTDC Tuscan Registry of
Congenital Defects
Table 2 Data in the primary care/prescription databases and the
congenital anomaly databases
CA database Prescription database
? - Total
? A B A ? B
- C D C ? D
Total A ? C B ? D A ? B ? C ? D
First trimester exposure rate according to CA registry data: % of
women exposed to medicine in the first trimester according to the CA
registry
(A ? B)/(A ? B ? C ? D) 9 100 %
First trimester exposure rate according to prescription data: % of
women exposed to medicine in the first trimester according to the
prescription database
(A ? C)/(A ? B ? C ? D) 9 100 %
Agreement of exposure according to the primary care/prescription
data: Number of women using medicine according to both CA reg-
istry and prescription database divided by the total number of women
with medicine prescribed in the prescription database
A/(A ? C) 9 100 %
Agreement of exposure according to the CA data: Number of women
using medicine according to both CA registry and prescription data-
base divided by the total number of women with medicine prescribed
in the CA registry
A/(A ? B) 9 100 %
The numbers per registry for each medicine are available at http://
www.euromedicat.eu/content/WP3%20Deliverable%2011%20Report.
pdf
CA congenital anomaly
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than the rates recorded in the CA registries for Wales,
Emilia Romagna and Tuscany. For antibacterials for sys-
temic use, the first trimester exposure rates recorded in the
primary care or prescription databases was much higher
than the rates in the CA registries. Furthermore, there was a
wide variation over the registries: for the CA registries, the
rates ranged from 1.84 % (Tuscany) to 10.12 % (Emilia
Romagna), while for the primary care or prescription
databases the rates ranged from 9.84 % (Norway) to
15.52 % (Emilia Romagna). The first trimester exposure
rates for the gonadotropins and other ovulation stimulants
were also higher in the prescription databases, except for
Wales.
The agreement according to the primary care/prescrip-
tion data and the agreement according to the CA data for
the first trimester is shown in Table 6. For the anti-epileptic
medicines and insulins and analogues, which are both used
for long-term conditions, the agreement between both
databases was generally relatively high. The SSRIs and
anti-asthmatics, which are also used in long-term condi-
tions, showed a lower agreement between the two data-
bases. Medicines for occasional use, such as antibacterials
for systemic use and gonadotropins and other ovulation
stimulants, showed a relatively low agreement between the
databases. Extending the time period by including the
month before the first trimester did not affect the findings
on anti-epileptic medicines and insulins and analogues to a
large extent, but the agreement according to the CA data
was increased for SSRIs and anti-asthmatics for some of
the registries (Table 7).
4 Discussion
We linked administrative databases to five CA registries
and evaluated the results of the linkage for six types of
common medicines. The linkage success varied between
registries over time and, for the Italian registries, by type of
birth. The first trimester exposure rates and the agreements
between the databases varied for the different medicine
groups. In general, information on anti-epileptic medicines
and insulins and analogue medicine use recorded by CA
registries was of good quality. For SSRIs, anti-asthmatics,
antibacterials for systemic use, and gonadotropins and
other ovulation stimulants, the recorded information was
less complete.
A major challenge in using prescription data is linking it
to all the cases of CAs, irrespective of pregnancy outcome.
For Norway and Odense, Denmark, linkage was possible
for most cases, as the linkage used personal identification
(ID) numbers, while the linkage success was lower for the
other registries. In Wales, GPs contribute to SAIL on a
voluntary basis; currently, 40 % of the GPs contribute and,
although this percentage is increasing, it reduces the
number of Welsh cases that could be linked. For Emilia
Romagna, the TOPFA cases could not be included in the
linkage because the CA registry does not have ID numbers
for the TOPFA cases or their mothers due to privacy reg-
ulations. As a result, the linked cases are biased towards the
less severe cases there. In Tuscany, an ID number for the
mother was only available for 52 % of the TOPFA cases.
Therefore, one should be aware that if not all cases can be
linked, there may be some bias in the results reported or the
linked dataset may not be suitable to analyse a possible
association between medication use and severe anomalies
that result frequently in terminations of pregnancy.
Medicines prescribed or dispensed before the first tri-
mester were not included in the first trimester definition of
the primary care or prescription databases. It is possible
that these medicines, although prescribed earlier, were also
taken in the first trimester and therefore registered in the
CA registry. Technically, there is a difference in the defi-
nition of the first trimester between the primary care or
prescription databases and the CA registries. However, we
Table 3 Linkage results per registry
Registry Wales,
n (%)
Norway,
n (%)
Odense,
Denmark,
n (%)
Emilia
Romagna,
n (%)
Tuscany,
n (%)
Years of inclusion 1998–2010 2004–2010 1998–2010 2004–2010 2003–2010
Total number of cases in CA registry 17,244 (100) 21,136 (100) 2006 (100) 6410 (100) 5823 (100)
Linked to prescription/primary care database 5472 (31.7) 20,874 (98.8) 2006 (100) 3172 (49.5) 3023 (51.9)
Total number of EUROCAT casesa linked to prescription
database (% calculated on linked cases)
5322 (97.3) 13,474 (64.5) 2006 (100) 3034 (95.6) 2716 (89.8)
CA congenital abnormality, CARIS Congenital Anomaly Register and Information Service, EUROCAT European Surveillance of Congenital
Anomalies, MBRN Medical Birth Registry from Norway, RTDC Tuscan Registry of Congenital Defects
a A EUROCAT case is defined as a child with major CA defined by the Q chapter of the International Classification of Diseases, 10th edition
(ICD-10), or in the range 740–759 of the International Classification of Diseases, 9th edition (ICD-9), and a very limited set of conditions not
included in the Q chapter [23]. Cases with only minor anomalies were excluded from the EUROCAT case definition
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expect the influence on the first trimester exposure rates to
be minimal, since the CA registries collect information on
medicine use mainly from medical files (except Tuscany)
in which medicine use is recorded as ‘used in the first
trimester’ rather than on a specific date. In addition, the
Norwegian CA registry and Emilia Romagna include
information on medicine used during any time in preg-
nancy, not specifically during the first trimester. Therefore,
misclassification of exposure cannot be ruled out; in par-
ticular, for medicines prescribed or taken at the start or
towards the end of the first trimester, there may be dis-
agreement between the information recorded in the CA
data and the prescription data.
For Emilia Romagna, relatively low rates of agreement
were found for medicines taken for long-term conditions.
The registry has now changed their data sources for med-
icine exposures and has added prescription information as a
data source.
In general, per registry, the anti-epileptic medicines and
insulins and analogues showed small differences between
the first trimester exposure rates recorded in the CA reg-
istries and the rates in the primary care or prescription
databases. In addition, the agreements between the primary
care/prescription databases and the CA registries were, in
general, relatively high. This was expected, since these
medicines are prescribed for long-term conditions and used
on a regular, daily basis; they are therefore well-recorded
in both medical files and prescription databases. However,
we noted 98 cases in which insulin (54) and anti-epileptics
(44) were recorded as prescribed in primary care or
Table 5 First trimester exposure rates for congenital abnormality data and the primary care/prescription data for Wales, Norway, Odense,
Denmark, Emilia Romagna, and Tuscany (%)
Medicine subgroup (EUROmediCAT) ATC code starting with Wales Norway Odense,
Denmark
Emilia
Romagna
Tuscany
CA PrX CA PrX CA PrX CA PrX CA PrX
Years of inclusion 1998–2010 2004–2010 1998–2010 2004–2010 2003–2010
Number of cases 5322 13,474 2006 3034 2716
Anti-epileptics N03A 0.77 0.66 0.46 0.50 0.55 0.60 0.26 0.33 0.59 0.52
Insulins and analogues A10A 1.01 0.70 1.25 0.91 0.65 0.70 0.43 0.36 0.70 0.37
Anti-asthmatics R03 4.47 5.58 1.74 1.89 3.14 3.24 2.11 2.74 0.37 2.39
SSRIs N06AB 1.05 3.44 0.62 0.79 1.65 1.74 0.33 0.69 0.41 1.44
Antibacterials for systemic use J01 2.87 12.78 6.43 9.84 – – 10.12 15.52 1.84 12.96
Gonadotropins and other ovulation
stimulants
G03G 1.16 0.34 0.10 3.03 – – 0.69 1.05 0.07 1.58
ATC Anatomical Therapeutic Chemical, CA congenital anomaly registry, PrX prescription or primary care database, SSRIs selective serotonin
reuptake inhibitors, – indicates data were not retrieved
Table 6 Comparison of parameters based on the first trimester (day 0 to day 97)
Medicine subgroup
(EUROmediCAT)
ATC code
starting
with
Agreement according to the prescription/primary
care data (%)
Agreement according to the CA data (%)
Wales Norway Odense,
Denmark
Emilia
Romagna
Tuscany Wales Norway Odense,
Denmark
Emilia
Romagna
Tuscany
Anti-epileptics N03A 77.1 63.2 91.7 40.0 71.4 65.9 69.4 100.0 50.0 62.5
Insulins and
analogues
A10A 81.1 71.5 71.4 63.6 60.0 55.6 52.4 76.9 53.8 31.6
Anti-asthmatics R03 33.3 33.5 58.5 19.3 6.2 41.6 36.3 60.3 25.0 40.0
SSRIs N06AB 22.4 38.3 74.3 19.0 17.9 73.2 48.8 78.8 40.0 63.6
Antibacterials for
systemic use
J01 7.8 16.4 – 27.8 6.3 34.6 25.2 – 42.7 44.0
Gonadotropins and
other ovulation
stimulants
G03G 27.8 1.5 – 21.9 2.3 8.1 42.9 – 33.3 50.0
ATC Anatomical Therapeutic Chemical, CA congenital anomaly, SSRIs selective serotonin reuptake inhibitors, – indicates data were not
retrieved
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prescription databases, but not recorded in or abstracted
from the medical files, which are the main data source for
the CA registries. Such omissions from the medical records
could have serious clinical consequences, unless more
accurate histories were taken on admission for delivery.
For the anti-asthmatics, small differences were found
between the first-trimester exposure rates recorded in the
CA registries and the primary care or prescription database
per registry. However, the agreements between the primary
care/prescription databases and the CA registries were, in
general, relatively low. The most plausible explanation for
this is that some anti-asthmatics are often taken ‘as nec-
essary’. It is possible that they were dispensed before the
first trimester, and were therefore not present in the pre-
scription database as a first-trimester prescription, but that
they were indeed used in the first trimester and therefore
recorded in the CA registry. Extending the relevant period
to include the month before pregnancy increased the
agreement for anti-asthmatics and SSRIs. This emphasises
that the timeframe used in the definition of the first tri-
mester may differ for medicines depending on prescribing
characteristics. Other explanations for low agreement could
be that the prescribed medicines were not taken (non-
compliance) or that the medicines were taken but their use
was not recorded. Medicines may not be recorded in
medical files for several reasons: women may forget; the
midwife may not ask the woman about medicine use when
taking the initial medical history, or the question may be
asked in a perfunctory manner, so that the woman does not
realise the importance of an accurate medical history;
women may be uncertain of the starting date of their first
trimester; medication use may be mentioned but not
recorded in the medical file; or the medicine was prescribed
after the first antenatal visit and therefore not recorded in
the medical file. Some CA registry records did not give the
full name of the medicines taken, so no ATC code could be
matched to the prescription database: for example, if the
woman cannot name her specific medicine, just ‘taking
antidepressant’ may be recorded. When no information is
found in medical records on maternal medication use,
registries may either interpret this as ‘no medication taken’
or ‘medication use unknown’. The use of administrative
data may overcome this problem.
For the SSRIs, the first trimester exposure rates recorded
in the primary or prescription database were two to three
times higher than the rates recorded in some CA registries.
Furthermore, SSRIs had a relatively low agreement
according to the primary care/prescription data. The high
rate of non-reporting of antidepressants suggests that
records might be biased by the stigma surrounding mental
illness. This may lead to either non-adherence with pre-
scribed regimens or non-reporting. Reporting of anti-
epileptic prescriptions (often for mental illness) may have
been similarly affected.
For the antibacterials for systemic use, the rates found in
the primary care or prescription databases were much
higher than the rates in CA registries and there were dif-
ferences between the registries. The agreements according
to both the primary care/prescription databases and the CA
registries were, in general, relatively low. It is likely that,
by the time of their interviews with the midwife, some
women had forgotten having a short course of antibacterial
agents. The differences across the registries can be
explained by differences in the prescribing behaviour seen
between the regions.
For gonadotropins and other ovulation stimulants, rates
in the primary care or prescription databases were gener-
ally higher than the rates in CA registries, whereas the
Table 7 Comparison of parameters based on the broad definition of the first trimester (day -31 to day 97)
Medicine subgroup
(EUROmediCAT)
ATC code
starting
with
Agreement according to the prescription/primary
care data (%)
Agreement according to the CA data (%)
Wales Norway Odense,
Denmark
Emilia
Romagna
Tuscany Wales Norway Odense,
Denmark
Emilia
Romagna
Tuscany
Anti-epileptics N03A 76.9 58.2 91.7 30.8 62.5 73.2 74.2 100 50 62.5
Insulins and
analogues
A10A 82.1 72.3 71.4 63.6 63.6 59.3 56.0 76.9 53.8 36.8
Anti-asthmatics R03 33.8 30.7 58.9 22.6 5.0 47.9 40.6 68.3 40.6 40.0
SSRIs N06AB 18.2 35.3 73.0 19.4 16.3 76.8 58.3 81.8 60.0 72.7
Antibacterials for
systemic use
J01 7.5 15.1 – 26.7 5.1 42.5 28.8 – 52.4 46
Gonadotropins and
other ovulation
stimulants
G03G 36.1 1.7 – 22.4 2.6 21.0 64.3 – 71.4 100
ATC Anatomical Therapeutic Chemical, CA congenital anomaly, SSRIs selective serotonin reuptake inhibitors, – indicates data were not
retrieved
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agreements according to both the primary care/prescription
database and the CA registries were, in general, relatively
low. Since these medicines are used in fertility treatments
and the prevention of miscarriages, non-compliance is a
less plausible explanation. The medicines were presumably
used but not recorded. For gonadotropins and other ovu-
lation stimulants, it is also possible that the woman did not
mention their use because she did not consider them as
medicines, or she was concerned about possible
stigmatisation.
In conclusion, we found that information on anti-
epileptics and insulins and analogues was fairly complete
in the CA registries, whereas for SSRIs, anti-asthmatics,
antibacterials for systemic use, and gonadotropins and
other ovulation stimulants, the information was less com-
plete. Therefore, the linkage held more added value for
SSRIs, anti-asthmatics, antibacterials for systemic use, and
gonadotropins and other ovulation stimulants.
In our project, the linkage was performed locally for all
registries and the linked datasets were kept locally,
according to the distributed database model. This was
necessary to comply with confidentiality regulations in
Odense, Denmark, Norway and Wales, where linked data
may not be sent outside the server. However, since large
datasets are needed to study the safety of medicine use in
pregnancy, the separate local datasets need to be combined
for further studies on the risk of medicines in pregnancy;
the ideal situation would be to collect and analyse such
linked data in a central unit.
For this project we used data from prescription data-
bases. In principle, prescription data contain the complete,
prospectively recorded, medication history, except for
over-the-counter medication and medications dispensed in
hospitals and private clinics. However, in Norway the
prescription database includes medicines dispensed to an
individual who collects them at a hospital pharmacy (out-
patient), but it does not include medicines given to indi-
viduals who are in hospital (inpatients). Furthermore, the
quality of prescription data is not affected by the woman’s
recall or the accuracy of healthcare professionals who
record medication use in medical files.
Nonetheless, this does not necessarily mean that
medicines prescribed or dispensed are actually taken [26].
However, we know from a Dutch cross-sectional study that
prescription data will most likely overestimate the expo-
sure, but this overestimation seems to be minimal, which
makes prescription records a reliable source for research
into associations between medication use in pregnancy and
CA [27].
The information on amount and dosage prescribed was
not available in a standard way (defined daily dose) in the
studied databases. Therefore, we could not include the
duration of the prescription in our definition of exposure
[22]. To improve the use of prescription data, information
on the amount prescribed and the daily dose should be
included in the administrative databases. In addition, more
uniformity concerning data definitions (ATC codes, med-
ication grouping, first trimester definition) should also be
taken into account to prevent bias.
In a previous Norwegian study, data of the NorPD and
MBRN, which were also included in this study, were linked
and compared by calculating the sensitivity, the specificity
and the positive predictive value (PPV) of recordedmedicine
in the MBRN for the period 2004–2007, using NorPD as the
‘gold standard’ [16]. It was possible to compare the Nor-
wegian study’s ‘sensitivity values’ to our values of agree-
ment according to the prescription database, and to compare
the ‘PPV values’ to our values of agreement according to the
CA registry. However, the Norwegian study did not provide
data on gonadotropins and other ovulation stimulants
specifically, while they did provide data on selective b2-
adrenoreceptor agonists (ATC code R03AC) and glucocor-
ticoids (ATC code R03BA) instead of anti-asthmatics in
general (ATC code R03). We found the values of sensitivity
and the agreement according to the prescription data for
Norway to be comparable. However, the values of the PPV
were higher in the Norwegian study than the values we cal-
culated for the agreement according to the CA registry for
Norway. This difference may be related to the fact that the
Norwegian study included all deliveries, while we only
included deliveries with a CA in the offspring.
In another study, administrative data relating to all
pregnancy events (which were classified as a birth, an
ectopic pregnancy or a termination of pregnancy) in
Western Australia were linked to a national database of
dispensed medicines for the period 2002–2005. This study
had a high linkage rate of health and other data due to very
few missed links (0.11 %) and low permanent migration
(2.7 %), and the researchers found that a medicine had
been dispensed to 28.0 % of women who had a pregnancy
event [28, 29].
5 Conclusion
We have described the linkage of primary care or pre-
scription databases to CA registries and shown that this
improves the quality of information on maternal use of
medicines in pregnancy, especially for some medicine
groups that are less fully registered in CA registries, such
as SSRIs, anti-asthmatics, antibacterials for systemic use,
and gonadotropins and other ovulation stimulants. How-
ever, if the prescribed medicine is not actually taken, the
use of prescription data may lead to an overestimation of
exposure. Possible selection bias towards specific types of
CA in the linked cases needs further attention.
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